MaxCyte, Inc. Issue of Equity from exercise of Share Options (0823R)
December 06 2016 - 4:34AM
UK Regulatory
TIDMMXCT
RNS Number : 0823R
MaxCyte, Inc.
06 December 2016
MaxCyte, Inc.
("MaxCyte" or the "Company")
Issue of Equity from exercise of Share Options
Maryland, USA - 06 December 2016: MaxCyte (LSE: MXCT), announces
the issue and allotment of 12,805 new ordinary shares of $0.01 each
in the Company (the "New Ordinary Shares") pursuant to the exercise
of share options by a certain option holder.
Application has been made for the New Ordinary Shares to be
admitted to trading on AIM and it is expected that admission will
take place on or around 09 December 2016. The New Ordinary Shares
will rank pari passu with the existing shares of the Company.
Following this allotment, the total issued share capital of the
Company will increase to 43,521,234 ordinary shares.
- ENDS -
For further information please contact:
MaxCyte +1 301 944 1660
Doug Doerfler, Chief Executive
Officer
Ron Holtz, Chief Financial
Officer
Nominated Adviser and Broker
Panmure Gordon
Freddy Crossley (Corporate
Finance)
Fabien Holler
Duncan Monteith
Tom Salvesen (Corporate Broking) +44 (0) 20 7886 2500
Financial PR Advisor +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
Lindsey Neville
About MaxCyte
MaxCyte is an established and revenue generating US-based
developer and supplier of cell engineering products and services to
biopharmaceutical firms engaged in cell therapy, drug discovery and
development, biomanufacturing, gene editing and immuno-oncology
markets, which independent market analyses estimate to be, in
aggregate, in excess of $35 billion in 2015. The Company's patented
flow electroporation technology enables its products to deliver
fast, reliable and scalable cell engineering to drive the research
and clinical development of a new generation of medicines.
MaxCyte's high performance platform allows transfection with any
molecule or multiple molecules and is compatible with nearly all
cell types, including hard-to-transfect human primary cells. It
also provides a high degree of consistency and minimal cell
disturbance, thereby facilitating rapid, large scale, clinical and
commercial grade cell engineering in a non-viral system and with
low toxicity concerns. The Company's cell engineering technology
platform is CE-marked and FDA-accredited, providing MaxCyte's
customers and partners with an established regulatory path.
Using the unique capabilities of its technology, MaxCyte is
developing CARMA, its proprietary platform in immuno-oncology, to
deliver a validated non-viral approach to CAR therapies across a
broad range of cancer indications, including solid tumors where
existing CAR-T approaches face significant challenges.
For more information visit http://www.maxcyte.com/
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEEANAKEDFKFEF
(END) Dow Jones Newswires
December 06, 2016 04:34 ET (09:34 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024